Novo Nordisk says experimental drug amycretin show 13% weight loss in trial  | Reuters News Agency


Business & FinanceHealth

Reuters was first to report on the early trial data for Novo Nordisk’s highly anticipated experimental drug amycretin which showed that participants had a weight loss of 13.1% after 12 weeks, prompting the company’s shares to rise to record highs and placing it above Tesla by market valuation. 

Market Impact

Shares surged more than 8% to record highs, shooting Novo Nordisk up in global rankings to the 12th most valuable company from 14 previously.

Article Tags

Topics of Interest: Business & FinanceHealth

Type: Reuters Best

Sectors: Business & FinancePharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Speed

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story


Source link